Zobrazeno 1 - 10
of 131
pro vyhledávání: '"Stephen, Barlas"'
Autor:
Stephen, Barlas
Publikováno v:
PT : a peer-reviewed journal for formulary management. 44(9)
The legal tactics that drug manufacturers use to extend drug patents may be the biggest impediment to lowering drug prices and to Congress acting on pricing. Until now, that is.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f56454be75414314dd3431fc38419e0a
https://pubmed.ncbi.nlm.nih.gov/31485141
https://pubmed.ncbi.nlm.nih.gov/31485141
Autor:
Stephen, Barlas
Publikováno v:
PT : a peer-reviewed journal for formulary management. 44(8)
Congressional deliberations over several competing bills on drug-price transparency may generate some useful data but are unlikely to have any effect on prices.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::397b4afd7f8da69a665a71f00fa6df34
https://pubmed.ncbi.nlm.nih.gov/31447529
https://pubmed.ncbi.nlm.nih.gov/31447529
Autor:
Stephen, Barlas
Publikováno v:
PT : a peer-reviewed journal for formulary management. 44(7)
Will “All of Us” provide clues on the origins of various illnesses? Congress hopes that analyzing the medical and biological data of millions of people will boost precision medicine and help predict outcomes.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::97c8dbfcb2e060cab0b81232da9739ae
https://pubmed.ncbi.nlm.nih.gov/31258306
https://pubmed.ncbi.nlm.nih.gov/31258306
Autor:
Stephen, Barlas
Publikováno v:
PT : a peer-reviewed journal for formulary management. 44(6)
Several drug-price “remedy” bills are floating around Congress, with most being described as a “first step.” So why is no one referring to that step as significant?
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::526c1ba407b3ae43a4b0f4a910bedb55
https://pubmed.ncbi.nlm.nih.gov/31160865
https://pubmed.ncbi.nlm.nih.gov/31160865
Autor:
Stephen, Barlas
Publikováno v:
PT : a peer-reviewed journal for formulary management. 44(6)
Since the introduction of the 2009 HITECH Act, how has system-wide data sharing fared among hospitals and physician offices? Not that well, according to the CMS. But will the new proposed rules improve things for providers, system developers, and pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d394eef7574e7594fa7c4ca01df348e6
https://pubmed.ncbi.nlm.nih.gov/31160869
https://pubmed.ncbi.nlm.nih.gov/31160869
Autor:
Stephen, Barlas
Publikováno v:
PT : a peer-reviewed journal for formulary management. 44(3)
What role, if any, do group purchasing organizations play in drug shortages?
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6c9ac1c19be6e191755c55d7d7ce26f2
https://pubmed.ncbi.nlm.nih.gov/30828227
https://pubmed.ncbi.nlm.nih.gov/30828227
Autor:
Stephen, Barlas
Publikováno v:
PT : a peer-reviewed journal for formulary management. 44(2)
Will the new opioid abuse bill prove more effective than its predecessor? A plethora of provisions will have little impact on pharmacists and pharmaceuticals.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e19bf689e6c1420143639e227290d105
https://pubmed.ncbi.nlm.nih.gov/30766006
https://pubmed.ncbi.nlm.nih.gov/30766006
Autor:
Stephen, Barlas
Publikováno v:
PT : a peer-reviewed journal for formulary management. 43(10)
President Donald Trump’s wide-ranging Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs has implications for P&T committees, PBMs, drug manufacturers, insurers, and of course, patients. As with everything else involving health care, it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0d73f6d68d3c94b419d68db23802e3c1
https://pubmed.ncbi.nlm.nih.gov/30271104
https://pubmed.ncbi.nlm.nih.gov/30271104
Congress Readying User Fee Program for OTC Products: Money Needed to Dig FDA Out of Its Review Ditch
Autor:
Stephen, Barlas
Publikováno v:
PT : a peer-reviewed journal for formulary management. 43(9)
Questions about the safety and efficacy of cough and cold medicines and numerous other over-the-counter (OTC) products—along with an overwhelmed, understaffed FDA—are the driving force behind Congressional action to put a first-ever OTC user fee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::826d4b8877b3fba7f26e4990e7db3afb
https://pubmed.ncbi.nlm.nih.gov/30186025
https://pubmed.ncbi.nlm.nih.gov/30186025
Autor:
Stephen, Barlas
Publikováno v:
PT : a peer-reviewed journal for formulary management. 43(8)
FDA guidance on outsourcing facilities and 503A pharmacies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::13c573e71ebf750549d8f864ae0e20d6
https://pubmed.ncbi.nlm.nih.gov/30100684
https://pubmed.ncbi.nlm.nih.gov/30100684